File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression

TitleTMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression
Authors
Issue Date2012
Citation
Cancer Research, 2012, v. 72 n. 13, p. 3270-3281 How to Cite?
AbstractFrequent gene amplification of the receptor-activated calcium-dependent chloride channel TMEM16A (TAOS2 or ANO1) has been reported in several malignancies. However, its involvement in human tumorigenesis has not been previously studied. Here, we show a functional role for TMEM16A in tumor growth. We found TMEM16A overexpression in 80% of head and neck squamous cell carcinoma (SCCHN), which correlated with decreased overall survival in patients with SCCHN. TMEM16A overexpression significantly promoted anchorageindependent growth in vitro, and loss of TMEM16A resulted in inhibition of tumor growth both in vitro and in vivo. Mechanistically, TMEM16A-induced cancer cell proliferation and tumor growth were accompanied by an increase in extracellular signal-regulated kinase (ERK)1/2 activation and cyclin D1 induction. Pharmacologic inhibition of MEK/ERK and genetic inactivation of ERK1/2 (using siRNA and dominant-negative constructs) abrogated the growth effect of TMEM16A, indicating a role for mitogen-activated protein kinase (MAPK) activation in TMEM16A-mediated proliferation. In addition, a developmental small-molecule inhibitor of TMEM16A, T16A-inh01 (A01), abrogated tumor cell proliferation in vitro. Together, our findings provide a mechanistic analysis of the tumorigenic properties of TMEM16A, which represents a potentially novel therapeutic target. The development of small-molecule inhibitors against TMEM16A may be clinically relevant for treatment of human cancers, including SCCHN. ©2012 AACR.
Persistent Identifierhttp://hdl.handle.net/10722/194426
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorDuvvuri, U-
dc.contributor.authorShiwarski, DJ-
dc.contributor.authorXiao, D-
dc.contributor.authorBertrand, C-
dc.contributor.authorHuang, X-
dc.contributor.authorEdinger, RS-
dc.contributor.authorRock, JR-
dc.contributor.authorHarfe, BD-
dc.contributor.authorHenson, BJ-
dc.contributor.authorKunzelmann, K-
dc.contributor.authorSchreiber, R-
dc.contributor.authorSeethala, RS-
dc.contributor.authorEgloff, AM-
dc.contributor.authorChen, X-
dc.contributor.authorLui, VW-
dc.contributor.authorGrandis, JR-
dc.contributor.authorGollin, SM-
dc.date.accessioned2014-01-30T03:32:34Z-
dc.date.available2014-01-30T03:32:34Z-
dc.date.issued2012-
dc.identifier.citationCancer Research, 2012, v. 72 n. 13, p. 3270-3281-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/194426-
dc.description.abstractFrequent gene amplification of the receptor-activated calcium-dependent chloride channel TMEM16A (TAOS2 or ANO1) has been reported in several malignancies. However, its involvement in human tumorigenesis has not been previously studied. Here, we show a functional role for TMEM16A in tumor growth. We found TMEM16A overexpression in 80% of head and neck squamous cell carcinoma (SCCHN), which correlated with decreased overall survival in patients with SCCHN. TMEM16A overexpression significantly promoted anchorageindependent growth in vitro, and loss of TMEM16A resulted in inhibition of tumor growth both in vitro and in vivo. Mechanistically, TMEM16A-induced cancer cell proliferation and tumor growth were accompanied by an increase in extracellular signal-regulated kinase (ERK)1/2 activation and cyclin D1 induction. Pharmacologic inhibition of MEK/ERK and genetic inactivation of ERK1/2 (using siRNA and dominant-negative constructs) abrogated the growth effect of TMEM16A, indicating a role for mitogen-activated protein kinase (MAPK) activation in TMEM16A-mediated proliferation. In addition, a developmental small-molecule inhibitor of TMEM16A, T16A-inh01 (A01), abrogated tumor cell proliferation in vitro. Together, our findings provide a mechanistic analysis of the tumorigenic properties of TMEM16A, which represents a potentially novel therapeutic target. The development of small-molecule inhibitors against TMEM16A may be clinically relevant for treatment of human cancers, including SCCHN. ©2012 AACR.-
dc.languageeng-
dc.relation.ispartofCancer Research-
dc.titleTMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1158/0008-5472.CAN-12-0475-T-
dc.identifier.pmid22564524-
dc.identifier.scopuseid_2-s2.0-84863586989-
dc.identifier.volume72-
dc.identifier.issue13-
dc.identifier.spage3270-
dc.identifier.epage3281-
dc.identifier.isiWOS:000307350700017-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats